Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | CDC25B | P30305 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PTPRC | P08575 | 5/20 | 0.48 |
| ▸ | S100A4 | P26447 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 3/20 | 0.48 |
| ▸ | ATG4B | Q9Y4P1 | 3/20 | 0.48 |
| ▸ | APAF1 | O14727 | 2/20 | 0.48 |
| ▸ | TDP2 | O95551 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2372163 | 0.98 | MEN1 (0.52) | NPC1RAB9AALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL30434925 | 0.98 | MEN1 (0.52) | NPC1RAB9AALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL7551452 | 0.96 | MEN1 (0.50) | NPC1RAB9AALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL27878197 | 0.91 | MAOA (0.46) | NPC1RAB9AALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL23598506 | 0.87 | ALDH1A1 (0.48) | NPC1RAB9AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL6556666 | 0.87 | ALDH1A1 (0.48) | NPC1RAB9AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL20724667 | 0.87 | ALDH1A1 (0.48) | NPC1RAB9AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL20724666 | 0.87 | ALDH1A1 (0.48) | NPC1RAB9AALDH1A1SMN1; SMN2MEN1 | |
| Fluorene SCHEMBL6852310 | 0.86 | MAOA (0.55) | NPC1RAB9AALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL9100646 | 0.82 | NPC1 (0.48) | NPC1RAB9AALDH1A1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020223517-A1 | METHODS OF MAKING OLIGOPOTENT AND UNIPOTENT PRECURSORS | TRANSFUSION HEALTH, LLC (US) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020186840-A1 | COMPOUND CONTAINING FLUORENE RING STRUCTURE AND APPLICATION THEREOF | 广州同隽医药科技有限公司 | 2020-09-24 | — | — | WO | disclosed |
| EP-1392643-B1 | TRISUBSTITUTED-N- (1S)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL] BENZAMIDES WHICH INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS | ABBOTT LAB (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6831193-B2 | Treating pain, urinary incontinence and bladder overactivity; P2X receptors are cation-permeable ion channels | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1392643-A2 | TRISUBSTITUTED-N- (1S)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL] BENZAMIDES WHICH INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS | Abbott Laboratories (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | ABBVIE INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2002094767-A2 | TRISUBSTITUTED-N-[(1S)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL] BENZAMIDES WHICH INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS | ABBOTT LABORATORIES (US) | 2002-11-28 | — | — | WO | disclosed |
| US-20020173665-A1 | Trisubstituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit P2X3 and P2X2/3 containing receptors | ABBOTT LABORATORIES | 2002-11-21 | — | — | US | disclosed |
| EP-1023293-A4 | ARYLOXYMETHYL CARBAPENEM ANTIBACTERIALS | MERCK & CO INC (US) | 2002-11-20 | — | — | EP | disclosed |
| EP-1023293-A1 | ARYLOXYMETHYL CARBAPENEM ANTIBACTERIALS | Merck & Co., Inc. (US) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999014217-A1 | ARYLOXYMETHYL CARBAPENEM ANTIBACTERIALS | MERCK & CO., INC. (US) | 1999-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173665-A1 | Trisubstituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit P2X3 and P2X2/3 containing receptors | P2RX3, P2RX1, P2RX2 | NPC1 4035/4885RAB9A 2807/4885ALDH1A1 404/4885 |
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | P2RX3, P2RX1, P2RX2 | NPC1 4215/4885RAB9A 2982/4885ALDH1A1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.